研究成果の刊行物に関する一覧表レイアウト

雑誌

発表者氏名	論文タイトル	発表誌名	巻号	ページ
Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, Asaga T, Minami H, Yamamoto N, Aogi K, Ikeda T, Ohashi Y, Sato W, Tsuruo T.	Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.	J Clin Oncol	25	411-417
Yamaguchi T, Bando H, Mori T, Takahashi K, Matsumoto H, Yasutome M, Weich H, Toi M.	Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis.	Cancer Sci	98	405-410
Suzuki E, Toi M.	Improving the efficacy of trastuzumab in breast cancer.	Cancer Sci	98(6)	767-771
Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S.	Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.	Clin Cancer Res	13(11)	3198-3206
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y; for Japan Breast Cancer Research Group (JBCRG).	Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival.	Breast Cancer Res Treat	110(3)	531-539
Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, Toi M, Yamamoto N.	Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo.	Breast Cancer Res Treat	104(3)	267-275
Toi M, Ikeda T, Akiyama F, Kurosumi M, Tsuda H, Sakamoto G, Abe O.	Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.	Int J Oncol	31(4)	899-906

戸井雅和	乳癌のホルモン療法—最新動向	医学のあゆみ	221(2)	133
戸井雅和	がん分子標的治療の最先端	医学のあゆみ	224(1)	1
戸井雅和	抗VEGF療法(乳腺)－原発性乳癌に対する治療応用が視野に	医学のあゆみ	224(1)	11-15
山城大泰、戸井雅和	Herceptin (trastuzumab)	癌と化学療法	34(8)	1173-1176
増田慎三、戸井雅和、高塚雄一、中村清吾、岩田広治、大野真司、黒井克昌、日馬幹弘、久松和史、山崎弘資、辛　栄成、佐藤康幸、海瀬博史、柏葉匡寛、岩瀬弘敬、黒住昌史、津田均、秋山太	乳癌周術期化学療法の現状およびSupportive Careの工夫	(特集　Neoadjuvant Therapyの適応と効用・Ⅰ) 癌と化学療法	34(10)	1609-1615
高田正泰、戸井雅和	乳癌－プライマリーケモテラピー－	(特集　Neoadjuvant Therapyの適応と効用・Ⅱ) 癌と化学療法	34(11)	1730-1734
上野貴之、戸井雅和	分子プロファイリングに関する進歩	「Breast and Endocrine Tumor」乳癌(原発性乳癌) 癌と化学療法	34(13)	2218-2223
上野貴之、戸井雅和	バイオマーカーと乳癌治療	細胞工学	26(9)	1026-1030
加藤大典、戸井雅和	2007年の乳癌術後補助化学療法	(がん診療の最前線)最新医学	62	1282-1292
加藤大典、戸井雅和	「新しい診断と治療のABC　51　内分泌5 乳癌」	最新医学別冊、遠藤登喜子(編) 最新医学社		208-218
倉田昌直、鶴田耕二、戸井雅和	血管新生抑制薬の可能性	外科(特集肝細胞切除後の長期成績向上を目指して)	69(5)	553-563

山城大泰、戸井雅和	Adjuvantcare としての化学療法とホルモン療法の使い分け	「乳癌—乳癌治療の最適化、化学ホルモン療法の現状と今後(ホルモン療法)」カレントセラピー	25(8)	676-680
戸井雅和、岩田広治	HER familyをターゲットとした分子標的治療 Anti-HER therapy	がん分子標的治療	5(1)	6-13
鈴木栄治、戸井雅和	解説・特集 HER familyをターゲットとした分子標的治療 Interface on Cancer Therapy 乳がんに対するトラスツズマブ治療効果におけるさらなる改善の可能性	がん分子標的治療	5(1)	14-21
Kuroi K, Toi M	Antiangiogenic property of metronomic chemotherary	New Research on Angiogenesis Inhibitors, 2007 Nove Science Publishers, Inc		55-76
Toi M, Yoshida R, Dewan Z, Yamaoka S, Yamamoto N	Inhibition of angiogenesis by antiinflammatory drugs	Transworld Research Network		549-559
Toi M	Long-term outcomes of aromatase inhibition for breast cancer.	Lancet Oncol	9(1)	8-10
Noguchi S, Toi M.	Molecular target therapy: basics and clinical application.	Breast Cancer	15(1)	47-48
戸井雅和、佐谷秀行、笹野公伸	細胞死	がん分子標的治療	6(3)	6-14
Chow LW, Yip AY, Loo WT, Toi M.	Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer.	J Steroid Biochem Mol Biol	#####	443-447
Chow LW, Yip AY, Loo WT, Toi M.	Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.	Cancer Lett	262(2)	232-238
Ueno T, Elmberger G, Weaver TE, Toi M, Linder S.	The aspartic protease napsin A suppresses tumor growth independent of its catalytic activity.	Lab Invest	88(3)	256-263

Ishiguro H, KitanoT,Yoshibayashi H, Toi M, Ueno T,Yasuda H, Yanagihara K, Garbo C.L, Fukushima M.	Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.	Annals of Oncology	19(5)	1019-1020
西尾和人、戸井雅和、塩津行正、鶴尾隆	がんバイオマーカー 研究の現状と展望	ヒューマンサイエンス	19(2)	4-11
戸井雅和、岩田広治、近藤正英	トラスツブマブの臨床的評価と医療経済評価	日経メディカル	Spring	26-31
山城大泰　戸井雅和	特集80才以上高齢者のがん治療を考える 乳癌	外科治療	99(2)	144-149
山城大泰　戸井雅和	特集　遺伝子多型がん薬物療法薬 TrastuzumabとFcγ	癌と化学療法	35(7)	1097-1100
戸井雅和、芳林浩史、河口浩介、多久和晴子、山崎万梨子、上野貴之、杉江知治	センチネルリンパ節	Cancer Board 乳癌、State of the ART	ep 1(1)	12-18
戸井雅和	乳がん治療における新しい標的療法の可能性	日本薬理学雑誌	132(3)	177-179
高田正泰、石黒洋、戸井雅和	化学療法	乳癌レビュー2009/メディカルレビュー社	1月	139-151
高田正泰、戸井雅和	ホルモン療法	乳癌レビュー2009/メディカルレビュー社	1月	123-138
河口浩介、山城大泰、戸井雅和	分子標的治療薬への期待 特集:乳癌診療の最新情報	PharmaMedeica	27(2)	47-52

雑誌

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Ueno M, Kiba T, Nishimura T, Kitano T, Yanagihara K, Yoshikawa K, Ishiguro H, Teramukai S, Fukushima M, Kato H, Inamoto T	Changes in survival during the past two decades for breast cancer at the Kyoto University Hospital.	Eur J Surg Oncol.	33(6)	696-699	2007
Takayoshi Kiba, Takashi Inamoto, Tsutomu Nishimura, Masaya Ueno Kazuhiro Yanagihara, Satoshi Teramukai, Hironori Kato, Masakazu Toiand Masanori Fukushima	The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery.	BMC Cancer	Nov7(8)	323	2008
Wakako Tsuji, Takashi Inamoto, Hiroyasu Yamashiro, Takayuki Ueno, Hironori Kato, Yu Kimura, Yasuhiko Tabata, Masakazu Toi	Adipogenesis Induced by Human Adipose Tissue-Derived Stem Cells	Tissue Engineering: Part A	15(1)	83-93	2008

雑誌

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Sato S, Arita M, Soga T, Nishioka T, Tomita M.	Time-resolved metabolomics reveals metabolic modulation in rice foliage.	BMC Syst Biol.	2	51	2008
Shinoda K, Tomita M, Ishihama Y.	Aligning LC peaks by converting gradient retention times to retention index of peptides in proteomic experiments.	Bioinformatics.	24(14)	1590-5	2008
Ohno H, Naito Y, Nakajima H, Tomita M.	Construction of a biological tissue model based on a single-cell model: a computer simulation of metabolic heterogeneity in the liver lobule.	Artif Life.	14(1)	3-28	2008
Shinoda K, Sugimoto M, Tomita M, Ishihama Y.	Informatics for peptide retention properties in proteomic LC-MS.	Proteomics.	8(4)	787-98	2008
内藤泰宏	細胞・組織シミュレーションの現状　薬効・毒性の予測にむけて	ファルマシア	44(9)	885-889	2008

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	出版社名	出版地	出版年	ページ
Kuroi K, Toi M	Diagnostic and prognostic molecular markers in breast cancer	Eiso Hiyama, Keiko Hiyama	Transworld Research Network	India	2009	1-55

雑誌

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH.	Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).	Support Care Cancer.		Epub ahead of print	2008
Kuroi K, Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Watanabe T, Bain S, Hausheer FH.	A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.	Jpn J Clin Oncol.	38(11)	748-54	2008
Saji S, Kuroi K.	Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature.	Breast Cancer.	15(4)	262-9	2008
Masuda N, Toi M, Takatsuka Y, Nakamura S, Iwata H, Ohno S, Kuroi K, Kusama M, Hisamatsu K, Yamazaki K, Eisei S, Sato Y, Kaise H, Kashiwaba M, Iwase H, Kurosumi M, Tsuda H, Akiyama F; Japan Breast Cancer Research Group.	[Results of survey conducted on perioperative chemotherapy and supportive care in primary breast cancer (JBCRG01)]	癌と化学療法	34(10)	1609-15	2008
Ono M, Imai H, Kuroi K, Ohsumi S, Shimozuma K.	Quality of Japanese health care evaluated as hospital functions.	Breast Cancer	14(1)	88-91	2007

Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.	Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.	Breast Cancer	14(1)	81-7	2007
Kuroi K, Shimozuma K, Ohsumi S, Imai H, Ono M.	Current status of health outcome assessment of medical treatment in breast cancer.	Breast Cancer	14(1)	74-80	2007
Ohsumi S, Shimozuma K, Kuroi K, Ono M, Imai H.	Quality of life of breast cancer patients and types of surgery for breast cancer--current status and unresolved issues.	Breast Cancer	14(1)	66-73	2007
Shimozuma K, Imai H, Kuroi K, Ohsumi S, Ono M.	Recent topics of health outcomes research in oncology.	Breast Cancer	14(1)	60-5	2007

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Miki Y, Suzuki T, Sasano H.	Controversies of aromatase localization in human breast cancer-Stromal Versus parenchymal cells.	J Steroid Biochem Mol Biol.	106	97-101	2007
Usami S, Moriya T, Amari M, Suzuki A, Ishida T, Sasano H, Ohuchi N.	Reliability of prognostic factors in breast carcinoma determined by core needle biopsy.	Jpn J Clin Oncol.	37	250-255	2007
Sakuma M, Akahira J, Ito K, Niikura H, Moriya T, Okamura K, Sasano H, Yaegashi N.	Promoter methylation status of the Cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer.	Cancer science	98	380-386	2007
Miki Y, Suzuki T, Hatori M, Igarashi K, Aisaki KI, Kanno J, Nakamura Y, Uzuki M, Sawai T, Sasano H.	Effects of aromatase inhibitors on human osteoblast and osteoblast-like	Bone	40	876-87	2007
Akahira JI, Tokunaga H, Toyoshima M, Takano T, Nagase S, Yoshinaga K, Tase T, Wada Y, Ito K, Niikura H, Yamada H, Sato A, Sasano H,	Prognoses and Prognostic Factors of Carcinosarcoma, Endometrial Stromal Sarcoma and Uterine Leiomyosarcoma: A Comparison with Uterine Endometrial Adenocarcinoma.	Oncology.	71	333-340	2007
Suzuki T, Miki Y, Moriya T, Akahira J, Hirakawa H, Ohuchi N, Sasano H.	In situ production of sex steroids in human breast carcinoma.	Med Mol Morphol.	40	121-127	2007
Sasano H, Suzuki T, Moriya T.	Analysis of surrogate markers for target-specific therapy in breast Carcinomas using archival materials.	Biomed Pharmacother.	61	543-547	2007
Miki Y, Suzuki T, Sasano H.	Aromatase inhibitor and bone.	Biomed Pharmacother.	61	540-542	2007

Sasano H, Suzuki T, Miki Y, Moriya T.	Intracrinology of estrogens and androgens in breast carcinoma.	J Steroid Biochem Mol Biol.	108	181-185	2007
Ito M, Moriya T, Ishida T, Usami S, Kasajima A, Sasano H, Ohuchi N.	Significance of pathological evaluation for lymphatic vessel invasion in invasive breast cancer.	Breast Cancer.	14	381-387	2007
Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T, Horie K, Inoue S, Sasano H	Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.	Cancer Sci	98	644-51	2007
Suzuki T, Inoue A, Miki Y, Moriya T, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S, Sasano H.	Early growth responsive gene 3 (EGR3) in human breast carcinoma: a regulator of estrogen-mediated invasion and a potent prognostic	Endocrine-Related Cancer	14	279-292	2007
林　慎一	ホルモン療法奏効メカニズムと効果予測　ーエストロゲンシグナルを標的にー	医学のあゆみ	221 (2)	140-143	2007
林　慎一	乳癌　ー基礎・臨床研究のアップデートー　内分泌療法感受性予測因子	日本臨床	65	148-153	2007
松本光代、畠山　篤、坂本宙子、山口ゆり、笹野公伸、八重樫伸生、林　慎一	3次元マイクロアレイー乳癌の診断と治療効果予測への臨床応用を目指してー	東北大学医学部保健学科紀要	16(1)	19－25	2007

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Yutaka Kyono, Naoyuki Sugiyama, Koshi Imami, Masaru Tomita, and Yasushi Ishihama	Successive and Selective Release of Phosphorylated Peptides Captured by Hydroxy Acid–Modified Metal Oxide Chromatography	Journal of Proteome Research	7	4585–4593	2008
石濱泰，杉山直幸	シグナル伝達プロテオームの最前線	Pharma VISION NEWS	12	29–34	2008

研究成果の刊行に関する一覧表レイアウト

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Keiko Mita, Zhenhuan Zhang, Yoshiaki Ando, Tatsuya Toyama, Maho Hamaguchi, Shunzo Kobayashi, Shin-ichi Hayashi, Yoshitaka Fujii, Hirotaka Iwase and Hiroko Yamashita	Prognostic Significance of Insulin-like Growth Factor Binding Protein (IGFBP)-4 and IGFBP-5 Expression in Breast Cancer	Jpn J Clin Oncol	37	575-582	2007
Tetsuya Sogon, Shigeru Masamura, Shin-ichi Hayashi , Richard J. Santen , Kei Nakachi , Hidetaka Eguchi ,	Demethylation of promoter C region of estrogen receptor gene is correlated with its enhanced expression in estrogen-ablation resistant MCF-7 cells	Journal of Steroid Biochemistry & Molecular Biology	105	106-114	2007
Akio Inoue , Yuko Seino , Shunichi Terasaka , Shin-ichi Hayashi , Takao Yamori , Masao Tanji , Ryoiti Kiyama	Comparative proWling of the gene expression for estrogen responsiveness in cultured human cell lines	Toxicology in Vitro	21	741-752	2007
Yasuhiro Miki, Takashi Suzuki, Chika Tazawa, Yuri Yamaguchi, Kunio Kitada, Seijiro Honma, Takuya Moriya, Hisashi Hirakawa, Dean B. Evans, Shin-ichi Hayashi, Noriaki Ohuchi, and Hironobu Sasano,	Aromatase Localization in Human Breast Cancer Tissues: Possible Interactions between Intratumoral Stromal and Parenchymal Cells	Cancer Res	67(8)	3945-3954	2007
Takashi Suzuki, Yasuhiro Miki, Takuya Moriya, Jun-ichi Akahira, Takanori Ishida, Hisashi Hirakawa, Yuri Yamaguchi, Shin-ichi Hayashi and Hironobu Sasano	5a-Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production	Int.J.Cancer	120	285-291	2006
T Suzuki, S Hayashi1, Y Miki, Y Nakamura, T Moriya, A Sugawara2, T Ishida3, N Ohuchi3 and H Sasano	Peroxisome proliferator-activated receptor g in human breast carcinoma: a modulator of estrogenic actions	Endocrine-Related Cancer	13	233-250	2006

研究成果の刊行に関する一覧表レイアウト

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Mitsuyo Matsumoto, Yuri Yamaguchi, Yuko Seino, Atsushi Hatakeyama, Hiroyuki Takei, Hitoshi Niikura, Kiyoshi Ito, Takashi Suzuki, Hironobu Sasano, Nobuo Yaegashi and Shin-ichi Hayashi	Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction	Endocrine-Related Cancer	15	451-463	2008
Hiromichi Niikawa, Takashi Suzuki, Yasuhiro Miki,Satoshi Suzuki, Shuji Nagasaki,Junichi Akahira, Seijiro Honma, Dean B. Evans, Shin-ichi Hayashi, Takashi Kondo, and Hironobu Sasano	Intratumoral Estrogens and Estrogen Receptors in Human Non ^Small Cell Lung Carcinoma	Human Cancer Biology	14	4417-4426	2008
Kojiro Tanabe,Hiroki Utsunomiya, Mitsutoshi Tamura, Hitoshi Niikura, Tadao Takano, Kohsuke Yoshinaga, Satoru Nagase,Takashi Suzuki, Kiyoshi Ito,Mitsuyo Matsumoto, Shin-ichi Hayashi and Nobuo Yaegashi	Expression of retinoic acid receptors in human endometrial carcinoma	Cancer Sci	99(2)	267-271	2008
Kojiro Tanabe, Mitsuyo Matsumoto, Shinya Ikematsu, Satoru Nagase, Atsushi Hatakeyama,Tadao Takano, Hitoshi Niikura, Kiyoshi Ito, Kenji Kadomatsu, Shin-ichi Hayashi and Nobuo Yaegashi	Midkine and its clinical significance in endometrial carcinoma	Cancer Sci	99(6)	1125-1130	2008
Shin-ichi Hayashi ,Yuri Yamaguchi	Estrogen signaling pathway and hormonal therapy	Breast Cancer	15	256-261	2008
Sin-ichi HayashiYuri Yamaguchi	Estrogen-Related Cancer Microenvironment of Breast Carcinoma	Endocrine J	56	1-7	2009
Masashi Kajiro, Ryuichi Hirota, Yuka Nakajima, Kaori Kawanowa, Kae Soma, Ichiaki Ito, Yuri Yamaguchi, Sho-hei Ohie, Yasuhito Kobayashi, Yuko Seino, Miwako Kawano, Yoh-ichi Kawabe, Hiroyuki Takei, Shin-ichi Hayashi, Masafumi Kurosumi, Akiko Murayama, Keiji Kimura and Junn Yanagisawa,	The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways	nature cell biology	On line	Feb. 8	2009
Shin-ichi Hayashia, Yuri Yamaguchib	Estrogen signaling in cancer microenvironment and prediction of response to hormonal therapy	Journal of Steroid Biochemistry and Molecular Biology	109	201-206	2008
Richard J. Santen*, Robert X. Song, Shigeru Masamura, Wei Yue, Ping Fan, Tetsuya Sogon, Shin-ichi Hayashi, Kei Nakachi, and Hidtek Eguchi	Adaptation to Estradiol Deprivation Causes Up-Regulation of Growth Factor Pathways and Hypersensitivity to Estradiol in Breast Cancer Cells	Adv Exp Med Biol	630	19-34	2008

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書　籍　名	出版社名	出版地	出版年	ページ
近藤正英	医療経済	戸井雅和	乳癌レビュー2009	メディカルレビュー社	大阪	2009	206-211

雑誌

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Kondo M, Toi M	Cost-effective treatment option in first-line therapy for advanced breast cancer in Japan	Expert Review of Anticancer Therapy	6(2)	197-204	2006
近藤正英, 星淑玲, 戸井雅和	乳癌高リスク者によるタモキシフェン予防内服の費用効果分析	日本公衆衛生雑誌	53(10S)	613	2006
近藤正英	トラスツズマブの経済評価－薬剤経済学－	がん分子標的治療	5(1)	70-76	2007
Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M	A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients	Clinical Cancer Research	13(6)	1875-1882	2007
近藤正英, 星淑玲, 戸井雅和	乳癌高リスク者によるホルモン療法剤予防内服の費用効果分析	日本公衆衛生雑誌	54(10S)	421	2007
近藤正英, 星淑玲, 戸井雅和	乳癌高リスク者によるホルモン療法剤予防内服のバジェット・インパクト	日本公衆衛生雑誌	55(10S)	408	2008
Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M	Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive,	Breast Cancer Research and Treatment	112(1)	175-187	2008

	early-stage breast cancer in Japan				
Kondo M, Hoshi SL, Toi M	Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan	British Journal of Cancer	100(2)	281-290	2009

研究成果の刊行に関する一覧表

論文

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
多根井智紀 増田慎三	乳頭分泌液中CEAにおけるイムノクロマトグラフィー（ICGA）法と酵素免疫測定(EIA)法の比較検討	乳癌の臨床	23(2)	23-128	2008
増田慎三	Current Organ topics-乳癌-乳がん治療における最近の進歩－個別化治療への挑戦	癌と化学療法	34(12)	2228-2235	2007
増田慎三	乳がん治療の現状と展望－個別化治療をめざして－	総合臨床	56(11)	3103-3105	2007

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書　籍　名	出版社名	出版地	出版年	ページ
増田慎三	科学的根拠に基づく乳がん診療ガイドライン2004-2007 解説	山口　徹	今日の治療方針2008	医学書院	東京	2009	1624-1631
増田慎三	マンモグラフィ読影の基本－典型的所見を呈する症例による読影－石灰化	遠藤登喜子	マンモグラフィ画像読影ハンドブック－乳がん検診における読影技術の向上を目指して	永井書店	大阪	2008	81-116
増田慎三	8. 治療薬の種類と特徴 1)抗癌剤	戸井雅和	インフォームドコンセントのための図説シリーズ乳癌薬物療法	医薬ジャーナル社	東京	2008	48-59

VOLUME 25 · NUMBER 4 · FEBRUARY 1 2007

JOURNAL OF CLINICAL ONCOLOGY

ORIGINAL REPORT

Dofequidar Fumarate (MS-209) in Combination With Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients With Advanced or Recurrent Breast Cancer

Toshiaki Saeki, Tadashi Nomizu, Masakazu Toi, Yoshinori Ito, Shinzaburo Noguchi, Tadashi Kobayashi, Taro Asaga, Hironobu Minami, Naohito Yamamoto, Kenjiro Aogi, Tadashi Ikeda, Yasuo Ohashi, Wakao Sato, and Takashi Tsuruo

From the National Shikoku Cancer Center, Matsuyama; Hoshi General Hospital, Koriyama; Japanese Foundation for Cancer Research, Tokyo; School of Medicine, Osaka University, Osaka; Nihon Schering K.K., Osaka; Kanagawa Cancer Center, Yokohama; National Cancer Center Hospital East, Kashiwa; Chiba Cancer Center, Chiba; Tokyo Metropolitan Komagome Hospital; The Jikei University School of Medicine; School of Medicine, Keio University; Biostatistics/Epidemiology and Preventive Health Sciences, University of Tokyo; Institute of Molecular and Cellular Biosciences, University of Tokyo, and Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.

Submitted July 17, 2006; accepted November 1, 2006; published online ahead of print at www.jco.org on December 18, 2006.

Supported by Schering AG, Berlin, Germany.

Presented in part at the 29th European Society for Medical Oncology Congress, Vienna, Austria, October 29–November 2, 2004, and the 27th San Antonio Breast Cancer Conference, San Antonio, TX, December 8-11, 2004.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Address reprint requests to Toshiaki Saeki, MD, PhD, Saitama Medical School Hospital, 38 Morohongo, Moroyama, Iruma-gun, Saitama 350-0495, Japan; e-mail: tsaeki@saitama-med.ac.jp.

0732-183X/07/2504-411/$20.00

DOI: 10.1200/JCO.2006.08.1646

A B S T R A C T

Purpose
To evaluate the efficacy and tolerability of dofequidar plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) therapy in comparison with CAF alone, in patients with advanced or recurrent breast cancer. Dofequidar is a novel, orally active quinoline derivative that reverses multidrug resistance.

Patients and Methods
In this randomized, double-blind, placebo-controlled trial, patients were treated with six cycles of CAF therapy: 28 days/cycle, with doxorubicin (25 mg/m^2) and fluorouracil (500 mg/m^2) administered on days 1 and 8 and cyclophosphamide (100 mg orally [PO]) administered on day 1 through 14. Patients received dofequidar (900 mg PO) 30 minutes before each dose of doxorubicin. Primary end point was overall response rate (ORR; partial or complete response). In total, 221 patients were assessable.

Results
ORR was 42.6% for CAF compared with 53.1% for dofequidar + CAF, a 24.6% relative improvement and 10.5% absolute increase (P = .077). There was a trend for prolonged progression-free survival (PFS; median 241 days for CAF *v* 366 days for dofequidar + CAF; P = .145). In retrospectively defined subgroups, significant improvement in PFS in favor of dofequidar was observed in patients who were premenopausal, had no prior therapy, and were stage IV at diagnosis with an intact primary tumor. Except for neutropenia and leukopenia, there was no statistically significant excess of grade 3/4 adverse events compared with CAF. Treatment with dofequidar did not affect the plasma concentration of doxorubicin.

Conclusion
Dofequidar + CAF was well tolerated and is suggested to have efficacy in patients who had not received prior therapy.

J Clin Oncol 25:411-417. © 2007 by American Society of Clinical Oncology

Despite the advances in chemotherapeutic intervention, many cancers are either inherently resistant or develop resistance to chemotherapy.[1,2] Consequently, multidrug resistance (MDR) remains a major obstacle to the successful treatment of cancer.[1,3,4] One mechanism by which MDR operates is via the increased cellular efflux of cytotoxic compounds due to increased expression of membrane transport proteins such as P-glycoprotein (P-gp) and MDR-associated protein (MRP).[1,4,5] MDR affects many structurally and functionally unrelated agents including cytotoxic drugs that are hydrophobic, natural products, such as taxanes, vinca alkaloids, anthracyclines, epipodophyllotoxins, topotecan, dactinomycin, and mitomycin.[1,6,7] These represent some of the most commonly used chemotherapeutic agents.

In tumors with low levels of P-gp expression at baseline or diagnosis, P-gp expression increases after exposure to chemotherapy agents, thus leading to the development of MDR. In breast cancer patients who had received prior chemotherapy, P-gp expression has been shown to increase from 11% in untreated patients to 30% after chemotherapy.[8] Furthermore, compared with P-gp–negative tumors, a significant increase in resistance to paclitaxel and doxorubicin was reported in P-gp positive breast cancer tissue, irrespective of prior therapy.

The degree of P-gp expression also strongly correlated with the degree of drug resistance observed.[8]

Chemotherapy remains the treatment of choice for women with hormone receptor–negative and hormone-refractory breast cancer disease.[9-11] However, many tumors that are initially responsive to chemotherapy frequently relapse and develop resistance to the broad spectrum of cytotoxic drugs currently employed.[8,12,13] Consequently, MDR remains a major reason for treatment failure in patients with metastatic breast cancer and highlights the urgent need for MDR modifiers in breast cancer chemotherapy.

Since the discovery of verapamil as an MDR-reversing agent,[14] many compounds have been investigated as MDR inhibitors.[14-16] Dofequidar fumarate (Fig 1), is a novel, orally active, quinoline-derived inhibitor of MDR.[17] In preclinical studies, dofequidar reversed MDR in P-gp– and MRP-1–expressing cancer cells in vitro (1 to 3 μmol/L), as well as enhancing the antitumor effects of doxorubicin in MDR tumor–bearing mice.[17-19] A phase I trial in healthy volunteers showed dofequidar to be well tolerated (10 to 1,200 mg) with no dose-limiting toxicities and an effective plasma concentration was maintained for 8 hours at 900 mg (data on file, Schering AG, Berlin, Germany). In a phase II combination trial in patients with recurrent breast cancer, dofequidar potentiated the antitumor effects of CAF (cyclophosphamide, doxorubicin, and fluorouracil) therapy; patients who had not responded to treatment with three cycles of CAF responded to subsequent treatment with dofequidar plus CAF. The numbers of patients with an objective response were two of seven at 600 mg and two of six at 900 mg dofequidar, though dose escalation was stopped at 1,200 mg due to increased hematologic toxicity (data on file, Schering AG). On the basis of this result, this phase III study was conducted to compare the efficacy and safety of dofequidar plus CAF with placebo plus CAF in patients with advanced or recurrent breast cancer.

Study Design

This was a randomized, multicenter, double-blind, placebo-controlled trial conducted at 46 centers across Japan, comparing the efficacy and safety of dofequidar plus CAF with placebo plus CAF. Female patients (age 20 to 70 years) with advanced (stage IV at diagnosis with an intact primary tumor) or recurrent breast cancer were enrolled onto the study. Other inclusion criteria included a histologically defined, measurable or assessable primary lesion; two or fewer regimens of prior chemotherapy in both neo/adjuvant and metastatic settings, (excluding prior endocrine or single-agent fluorouracil therapy); 180 mg/m^2 anthracyclines (doxorubicin equivalent) or less previously; a performance status of 0 to 2; and adequate bone marrow, renal, hepatic and cardiac functions. Patients who progressed or had a recurrence in less than 6 months with anthracycline-containing chemotherapy, and those who had a history of major cardiac disease, uncontrolled hypertension, symptomatic brain metastasis, or simultaneous malignancy were excluded. The trial was approved by the institutional review board and was conducted in accordance with the Declaration of Helsinki (1996). All patients provided written informed consent before study entry.



Fig 1. Structure of dofequidar (MS-209).

Dosing and Dose Modification for Toxicity

Patients were treated with six cycles of CAF therapy with dofequidar or placebo, and each treatment cycle lasted for 28 days; drugs were administered as follows: days 1 and 8, doxorubicin (25 mg/m^2) and fluorouracil (500 mg/m^2), each infused over 15 minutes; days 1 through 14, cyclophosphamide (100 mg orally [PO]); dofequidar (900 mg/d; 3 × 300 mg tablets) or placebo administered 30 minutes before each doxorubicin dose to ensure adequate blood concentration of dofequidar. The doses of doxorubicin and fluorouracil were reduced to 20 mg/m^2 and 400 mg/m^2, respectively, if any of the following criteria were met: grade 3 nonhematologic toxicity (except nausea and vomiting); grade 3 or worse neutropenia (< 1,000/mm^3) maintained for at least 5 days with an episode of fever of 38.5°C or higher; grade 3 or worse thrombocytopenia (< 50,000/mm^3); and grade 4 neutropenia (< 500/mm^3). The next cycle was postponed for 3 weeks unless the patient had a WBC count of at least 4,000/mm^3, or a neutrophil count of at least 2,000/mm^3 and a platelet count of at least 100,000/mm^3. Patients were followed up for 3 months after completion or discontinuation of treatment.

Treatment Assignment

Patients were randomly assigned to their treatment by the Trial Register Center. Treatment assignment was securely stored and coded until completion of the study. Investigators were also blinded to the assigned treatment. Patients were stratified by the number of prior chemotherapy regimens, including adjuvant chemotherapy, by a history of prior use of anthracyclines, and by the presence of liver metastases.

Efficacy

The primary study end point was the overall response rate (ORR) in the full analysis set (FAS; all patients who received treatment at least once and met all inclusion/exclusion criteria). Efficacy assessment by lesion and ORR assessment were made at each treatment cycle (every 4 weeks) and at treatment completion. Objective responses were assessed through blinded reading of radiographs by an independent expert panel. The secondary study end points included complete response rate (CR), time to treatment failure (TTF), time to progression (TTP), and progression-free survival (PFS).

Subgroup analyses were conducted to assess PFS within specific patient subpopulations, including premenopausal women, patients who had no prior therapy, and patients who had advanced primary breast cancer.

Safety and Tolerability

Adverse events (AEs) were recorded at the end of each treatment cycle and at the end of the study period using data from the safety population (all patients who received treatment at least once in the study). AEs were categorized according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2. The incidence of significant decreases in left ventricular ejection fraction (LVEF) and serious AEs were recorded. The CBC was evaluated weekly. Serum chemistries and urinalysis were evaluated every 2 weeks. The minimum hematology values and LVEF in each treatment cycle were also recorded and analyzed in the per-protocol set (PPS; all patients who received treatment at least once and had no protocol deviations).

Pharmacokinetics

To assess the effect of concomitant dofequidar use on the pharmacokinetics of doxorubicin, the plasma doxorubicin concentration on day 1 of cycle 1 was compared between treatment groups. Blood samples were taken at baseline and at 15 minutes, 30 minutes, and 1, 2, 4, and 6 hours after the start of doxorubicin administration. Plasma doxorubicin concentrations were determined by reversed-phase high-performance liquid chromatography. Area

under the plasma concentration-time curve (AUC) was calculated using the linear trapezoidal rule.

Statistical Analyses

The primary end point was analyzed using the Fisher's exact test at a significance level of 2.5% in a one-sided test. A difference in response rates of 20% between the two treatment groups was used as the basis for a statistically significant difference. CR, TTF, TTP and PFS were analyzed by the log-rank test at a significance level of 5% in a two-sided test. The CR, TTF, TTP and PFS were analyzed in the FAS, and the pharmacokinetic data analyzed in the PPS.

Patient Characteristics

A total of 227 patients were recruited onto the study (Fig A1, online only), of which 225 patients were included in the safety analysis (n = 113 for the dofequidar group; n = 112 for the placebo group); two patients did not receive the study treatment and were thus excluded. Four patients did not meet the inclusion/exclusion criteria; therefore, the FAS consisted of 221 patients (n = 113 for the dofequidar group; n = 108 for the placebo group). The PPS consisted of 199 patients (n = 100 for the dofequidar group; n = 99 for the placebo group). There were 22 patients excluded from the PPS analysis due to protocol deviations. Baseline patient characteristics were well balanced between the two treatment arms (Table 1). Most patients had predominantly recurrent disease and had received prior chemotherapy plus endocrine therapy. Also, many patients who had advanced primary breast cancer had received no prior therapy.

Table 1. Patient Demographics (full analysis set)

Charecteristic	Dofequidar + CAF (n = 113)		Placebo + CAF (n = 108)	
	No.	%	No.	%
Age, years				
Mean	54.4		52.4	
SD	7.69		8.97	
Medical history known	65	57.5	60	55.6
Weight, kg				
Mean	56.2		54.1	
SD	7.52		7.73	
Height, cm				
Mean	154.7		154.7	
SD	5.71		5.61	
Body surface area, m^2				
Mean	1.5		1.5	
SD	0.11		0.11	
Disease state				
Recurrent	81	71.7	80	74.1
Advanced	32	28.3	28	25.9
Prior therapy				
Radiotherapy + chemotherapy + endocrine therapy	32	22.1	32	29.6
Chemotherapy + endocrine therapy	55	48.7	54	50.0
Radiotherapy	1	0.9	1	0.9
No prior therapy	25	22.1	21	19.4
Menopausal status				
Premenopausal	24	21.2	26	24.1
Postmenopausal	88	77.9	79	73.1

Abbreviations: CAF, cyclophosphamide, doxorubicin, and fluorouracil; SD, standard deviation.

Efficacy

The ORR, rated as CR or partial response rate, was 42.6% for CAF plus placebo versus 53.1% for dofequidar plus CAF (Table 2). Although this represents a 24.6% relative improvement and a 10.5% absolute increase in response rate for patients receiving dofequidar plus CAF compared with those receiving CAF plus placebo, this response was not statistically significant ($P = .077$). A higher value was observed in the dofequidar treatment group for all secondary end points compared with placebo, though these results were not statistically significant. Among them, Figure 2 shows a trend for prolonged PFS (median, 241 days for CAF plus placebo *v* 366 days for dofequidar plus CAF; $P = .145$).

Dofequidar plus CAF significantly improved PFS in several patient subgroups, including patients who were premenopausal ($P = .046$; Fig 3A), patients who had not received prior therapy ($P = .0007$; Fig 3B), and patients who had advanced primary breast cancer ($P = .017$; Fig 3C). An extended follow-up showed that dofequidar plus CAF also significantly improved overall survival ($P = .0034$; Fig 3D) in patients who had no prior therapy.

Safety and Tolerability

A similar number of patients completed six treatment cycles in both groups (n = 53 for the dofequidar group; n = 51 for the placebo group). The mean number of treatment cycles was 4.5 in the dofequidar group and 4.3 in the placebo group. More than half of patients in both groups included in each cycle from cycle 2 onward had a delay in treatment, mostly due to prolonged hematologic toxicities.

Dofequidar plus CAF was well tolerated throughout the study. No statistically significant excess of grade 3/4 AEs, except for neutropenia ($P = .006$) and leukopenia ($P = .005$), was found in the dofequidar group compared with placebo (Table A1, online only). Importantly, there was no marked difference in the incidence of neutropenia-related morbidity, such as febrile neutropenia or infection, between the two treatment groups. No significant differences in the incidence of cardiac AEs were found between the two treatment groups. In addition, dose intensities of chemotherapeutic agents were similar in both treatment arms. No significant difference in the incidence of serious AEs (SAEs) was observed between either group. However, there was a trend for a higher incidence of SAEs from leukopenia in the dofequidar group, than in the placebo group ($P = .060$; Fisher's exact test); five leukopenia cases were reported for dofequidar, whereas no such case was reported for placebo.

A total of 124 patients discontinued the study (n = 61 for the dofequidar group; n = 63 for the placebo group). The major reasons for discontinuation were progressive disease (n = 23 for the dofequidar group; n = 28 for the placebo group), grade 4 hematologic toxicity (n = 20 for the dofequidar group; n = 6 for the placebo group), failure to meet treatment continuation criteria (n = 6 for the dofequidar group; n = 8 for the placebo group), and consent withdrawal (n = 6 for the dofequidar group; n = 12 for the placebo group). Of the 225 patients who received treatment in the study, 14 patients died during the treatment period (n = 3), the follow-up period (n = 2), or the follow-up period after study termination (n = 9). There were 49 other serious AEs in 32 patients during the study and follow-up period.

Pharmacokinetics

The mean plasma concentrations of doxorubicin in the dofequidar- and placebo-treatment groups at 15 minutes postadministration reached 0.997 μg/mL and 1.259 μg/mL, respectively, followed by biphasic elimination in both treatment groups. Mean plasma concentrations in

Table 2. Response Rates for Patients Treated With Dofequidar Plus CAF (n = 113) or Placebo Plus CAF (n = 108)

Treatment Group	Parameter (No. of patients)					Overall Response Rate (%)	95% CI
	Complete Response	Partial Response	No Change (stable disease)	Progressive Disease	Not Assessable		
Dofequidar	5	55	40	10	3	53.1	43.5 to 62.5
Placebo	4	42	41	14	7	42.6	33.1 to 52.5

NOTE. Odds ratio = 1.53 (range, 0.87-2.69), $P = .077$ for dofequidar *v* placebo.
Abbreviation: CAF, cyclophosphamide, doxorubicin, and fluorouracil.

the dofequidar and placebo groups remained similar at 1, 2, 4, and 6 hours after the start of doxorubicin administration. Thus the elimination pattern for the first 6 hours after the start of administration was similar in both groups. The plasma concentrations of doxorubicin in the terminal phase (4 and 6 hours postadministration) were slightly higher in the dofequidar group compared with placebo (1.2- to 1.3-fold). However, AUC (0 to 6 hours) values showed no statistically significant difference between the dofequidar and placebo groups (mean, 0.480 μg · h/mL; standard deviation [SD], 0.324; range, 0.237-1.692; and mean, 0.407 μg · h/mL; SD, 0.062; and range, 0.289-0.500, respectively). Therefore, treatment with dofequidar did not affect the plasma concentrations of doxorubicin in patients (Fig 4).

Chemotherapy remains the preferred adjuvant treatment for patients with hormone receptor–negative disease and for patients with more aggressive, hormone receptor–positive tumors.[11,20] However, despite the use of conventional adjuvant chemotherapy regimens, a significant proportion of patients with breast cancer still experience disease recurrence because of inherent or acquired drug resistance.[12] In this randomized phase III trial, the efficacy and safety of the multidrug resistance inhibitor dofequidar plus CAF was compared with CAF plus placebo in patients with recurrent or advanced breast cancer. Although, there was an observed relative improvement and absolute increase in response rate for patients who received dofequidar plus CAF, these results did not reach statistical significance. This improvement in response rate may have been reflected in the observation that there was a trend for prolonged PFS, which favored patients in the dofequidar plus CAF group.



Fig 2. Progression-free survival in patients treated with dofequidar plus cyclophosphamide, doxorubicin, and fluorouracil (CAF) and placebo plus CAF ($P = .145$).

To date, only two randomized trials have examined the efficacy of a P-gp inhibitor in combination with chemotherapy in breast cancer patients. Wishart et al[21] examined quinidine combined with epirubicin in patients with advanced breast cancer, but failed to show any significant difference in overall survival or PFS compared with placebo. In a more recent prospective study of patients with anthracycline-resistant metastatic breast cancer (n = 99), verapamil combined with vindesine and fluorouracil resulted in a significantly longer overall survival and a higher response rate compared with patients who did not receive the P-gp inhibitor (median survival, 323 *v* 209 days; $P = .036$, respectively; ORR, 27% *v* 11%; $P = .04$, respectively).[22]

In the subgroup analyses, dofequidar in combination with CAF displayed a significantly increased PFS in patients who had not received prior therapy, who had advanced primary breast cancer or who were premenopausal. In addition, dofequidar also significantly improved overall survival in the patient group who had no prior therapy. Although the patient numbers in these analyses were small, the results remain important within these clinically significant patient populations. Both preclinical and clinical data have indicated that newer-generation MDR modulators can prevent the development of resistance.[23,24] A phase I/II trial in patients with acute myeloid leukemia showed that dosing with cyclosporine before and in combination with daunorubicin prevented chemotherapy resistance, while also resulting in a decrease in MDR-1 RNA expression.[24] Our results may highlight one potential treatment approach to MDR tumors that has not yet been fully exploited in the clinical environment, specifically the prevention of the emergence of resistance through the early use of P-gp inhibitors.[1-3] It seems reasonable that agents such as dofequidar may be useful in the adjuvant or even neoadjuvant setting with the goal of preventing or delaying the induction of MDR associated with chemotherapy.

The potential clinical significance of P-gp and MRP expression in breast cancer is supported by the results from a number of studies. For example in a study of primary breast cancer patients (n = 259), MRP expression was associated with an increased risk of treatment failure in patients with small tumors (T1) and node-positive patients who received adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy but not in node-negative patients.[25] Burger et al[12] reported that the expression of MDR1 mRNA in primary breast tumors was inversely correlated with the efficacy of first-line chemotherapy. Additionally, the high level of MDR1 expression was suggested to be a significant predictor of poor prognosis in patients